Dermatophagoides pteronyssinus group 2 allergen (Der p 2)

Dermatophagoides pteronyssinus group 2 allergen, commonly known as Der p 2, is one of the most clinically significant major allergens produced by the European house dust mite. It is a 129-amino acid protein belonging to the Niemann-Pick type C2 (NPC2) family, characterized by a beta-cup structure that enables the binding of hydrophobic ligands such as cholesterol and fatty acids (UniProt: P49278). A key feature of Der p 2 is its structural and functional mimicry of MD-2, the LPS-binding component of the Toll-like receptor 4 (TLR4) complex. This mimicry allows Der p 2 to facilitate TLR4 signaling even in the absence of MD-2, thereby promoting the Th2-skewed immune environment characteristic of allergic sensitization (Nature: 10.1038/nature07920). In clinical practice, Der p 2 is a primary component of allergen-specific immunotherapy (AIT) products, such as Odactra and Acarizax, which are used to treat house dust mite-induced allergic rhinitis and asthma (FDA: Odactra Label). These therapies aim to induce immune tolerance by modulating T-cell responses, increasing regulatory T-cells, and promoting the production of protective IgG4 antibodies. Monitoring patient sensitivity to Der p 2 via specific IgE testing is essential for diagnosing house dust mite allergy and selecting candidates for desensitization therapy. The primary safety concern with targeting this allergen is the risk of IgE-mediated systemic reactions, including anaphylaxis, during the administration of immunotherapy.

Other names

Der p IIMajor mite allergen Der p 2NPC2-like allergen

Allergen-specific immunotherapy (AIT) induces peripheral T-cell tolerance, increases regulatory T-cells (Tregs), and promotes a shift from IgE to IgG4 antibody production to reduce allergic inflammation (PubMed: 27560118).